Poet T S, Brendel K, Halpert J R
Department of Pharmacology and Toxicology, University of Arizona, Tucson 85721.
Toxicol Appl Pharmacol. 1994 May;126(1):26-32. doi: 10.1006/taap.1994.1086.
Mechanism-based inactivators of rat liver cytochrome P450 2B1 and 2B2 were used to evaluate the role of these enzymes in the hepatotoxicity of cocaine. Loss of liver microsomal androstenedione 16 beta-hydroxylation was monitored to determine the extent of P450 2B1/2 inactivation by chloramphenicol (CAP) or its 2B-selective analogue, N-(2-p-nitrophenethyl)chlorofluoroacetamide (pNO2C1FA). The effect of P450 2B1/2 inactivation on cocaine-mediated hepatotoxicity was assessed in rat liver slices. Exposure of slices from phenobarbital-induced Lewis rats to CAP concentrations ranging from 100 to 500 microM resulted in a concentration-dependent decrease in P450 2B activity and a corresponding decrease in cytotoxicity as measured by K+ loss following exposure to 1 mM cocaine. Treating slices from PB-induced rats with 250 microM pNO2C1FA protected slices against cocaine-mediated cytotoxicity after exposure to 500 microM cocaine. In vivo administration of 300 mg/kg CAP or 200 mg/kg pNO2C1FA to phenobarbital-induced Lewis rats decreased androstenedione 16 beta-hydroxylation to 30 or 39% of control, respectively, and blocked cocaine-mediated K+ loss in rat liver slices. Rat liver microsomes from animals treated with either CAP or pNO2C1FA displayed approximately 40% of the control rate of cocaine N-demethylation. Experiments with phenobarbital-treated Munich Wistar (WM) rats, which lack 2B2, revealed similar rates of microsomal N-demethylation and comparable in vitro hepatotoxicity to Lewis rats. The capacity of a specific P450 2B1/2 inactivator to protect against cocaine-mediated hepatotoxicity both in vivo and in vitro and the results with the WM rats support the identification of P450 2B1 as a major cocaine bioactivating form.
基于机制的大鼠肝细胞色素P450 2B1和2B2失活剂被用于评估这些酶在可卡因肝毒性中的作用。通过监测肝微粒体雄烯二酮16β-羟基化的丧失来确定氯霉素(CAP)或其2B选择性类似物N-(2-对硝基苯乙基)氯氟乙酰胺(pNO2C1FA)对P450 2B1/2的失活程度。在大鼠肝切片中评估P450 2B1/2失活对可卡因介导的肝毒性的影响。将苯巴比妥诱导的Lewis大鼠的切片暴露于100至500微摩尔浓度的CAP中,导致P450 2B活性呈浓度依赖性降低,并且在暴露于1毫摩尔可卡因后,通过钾离子损失测量的细胞毒性相应降低。用250微摩尔pNO2C1FA处理苯巴比妥诱导大鼠的切片,可在暴露于500微摩尔可卡因后保护切片免受可卡因介导的细胞毒性。对苯巴比妥诱导的Lewis大鼠体内给予300毫克/千克CAP或200毫克/千克pNO2C1FA,分别使雄烯二酮16β-羟基化降低至对照的30%或39%,并阻断了大鼠肝切片中可卡因介导的钾离子损失。用CAP或pNO2C1FA处理的动物的大鼠肝微粒体显示可卡因N-去甲基化的对照速率约为40%。对缺乏2B2的苯巴比妥处理的慕尼黑Wistar(WM)大鼠进行的实验显示,微粒体N-去甲基化速率与Lewis大鼠相似,且体外肝毒性相当。一种特异性P450 2B1/2失活剂在体内和体外均能保护免受可卡因介导的肝毒性,以及WM大鼠的实验结果支持将P450 2B1鉴定为主要的可卡因生物活化形式。